| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $63.8M | -13.9% |
| SG&A Expense | $45.5M | +43.5% |
| Operating Income | -$109.3M | -3.3% |
| Pre-tax Income | -$99.7M | -1.4% |
| Income Tax | $0 | — |
| Net Income | -$100.0M | -1.7% |
| EPS (Basic) | -$1.86 | +39.8% |
| EPS (Diluted) | -$1.86 | +39.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $63.0M | +79.9% |
| Current Assets | $188.4M | +49.4% |
| Total Assets | $268.7M | +82.9% |
| Current Liabilities | $16.8M | -26.4% |
| Total Liabilities | $22.0M | -26.8% |
| Stockholders' Equity | $246.7M | +111.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$98.6M | -21.5% |
| Capital Expenditures | $397K | -17.5% |
| Investing Cash Flow | -$90.3M | +4.1% |
| Financing Cash Flow | $216.8M | +144.2% |
| Free Cash Flow | -$99.0M | -21.2% |